Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

[The quantitative determination method of covalently closed circular DNA HBV in puncture biopsy specimens of the liver.]

Tytuł:
[The quantitative determination method of covalently closed circular DNA HBV in puncture biopsy specimens of the liver.]
Autorzy:
Ostankova YV; Saint-Petersburg Pasteur Institute, 197191, Saint Petersburg, Russia.
Semenov AV; Saint-Petersburg Pasteur Institute, 197191, Saint Petersburg, Russia.; Saint-Petersburg State Medical University n.a. acad. I.P. Pavlov, 197022, Saint Petersburg, Russia.; North-West State Medical University n.a. I.I. Mechnikov, 191015, Saint Petersburg, Russia.
Totolian AA; Saint-Petersburg Pasteur Institute, 197191, Saint Petersburg, Russia.; Saint-Petersburg State Medical University n.a. acad. I.P. Pavlov, 197022, Saint Petersburg, Russia.
Źródło:
Klinicheskaia laboratornaia diagnostika [Klin Lab Diagn] 2019; Vol. 64 (9), pp. 565-570.
Typ publikacji:
Journal Article
Język:
Russian
Imprint Name(s):
Original Publication: Moskva : "Meditsina", 1992-
MeSH Terms:
DNA, Circular/*analysis
DNA, Viral/*analysis
Hepatitis B, Chronic/*diagnosis
Biopsy, Needle ; Hepatitis B Surface Antigens ; Hepatitis B virus ; Humans ; Liver ; Russia
Contributed Indexing:
Keywords: covalently closed circular DNA HBV; occult hepatitis B; сhronic hepatitis B
Substance Nomenclature:
0 (DNA, Circular)
0 (DNA, Viral)
0 (Hepatitis B Surface Antigens)
Entry Date(s):
Date Created: 20191015 Date Completed: 20191106 Latest Revision: 20200108
Update Code:
20240105
DOI:
10.18821/0869-2084-2019-64-9-565-570
PMID:
31610110
Czasopismo naukowe
To analyze the method HBV covalent-closed circular DNA quantitative determination in liver puncture biopsies and evaluate its significance in identifying HBsAg-negative viral hepatitis B. In this work, samples of liver tissue biopsy material were used from 128 patients living in St. Petersburg, in various regions of the Russian Federation, as well as in the Republic of Uzbekistan. For quantitative analysis of HBV covalently closed circular DNA in a biopsy material a method was developed based on real-time PCR using TaqMan probes for the target fragment and for the endogenous reference gene, based on the detecting ccc HBV DNA method of Pollicino T. et al. When quantifying ccc DNA HBV in liver tissue of 18 moderately HBV activity with HBV DNA PCR positive results patients and 16 inactive HBsAg carriers, the ccc DNA HBV content was significantly different between groups (p<0.034) and in terms 1 copy of the β-globin gene among moderate activity HBV patients amounted to 1.71±1.32 copies/cell, and for inactive HBsAg carriers 0.15±0.14 copies/cell. In the group of patients with severe liver fibrosis and cirrhosis, the amount of ccc DNA HBV in liver tissue in patients with HBV averaged 2.5±0.4 copies/cell, in patients with HBV + D on average 0.7±0.25 copies/cell, in patients with HCV + HBV co-infection 0.45±0.07 copies/cell, in patients with a preliminary diagnosis of chronic hepatitis C hepatitis, on average 0.12±0.04 copies/cell, in patients with cryptogenic hepatitis 0.2± 0.05 copies/cell. A significant difference was shown between the group of patients with chronic hepatitis B with marked fibrosis and cirrhosis of the liver with other patients groups, except for the group of 18 moderate activity chronic hepatitis B patients. The values of Student's t-test when compared with other groups were respectively: for patients with a HCV preliminary diagnosis t=5,92 p<0,05 f = 19, patients with cryptogenic hepatitis t=5,71 p<0,05 f = 18, with «inactive HBsAg carriage» t=5,55 p<0,05 f = 29, with HCV + HBV co-infection t=5,05 p<0,05 f = 15 and HBV + D co-infection t=3,82 p<0,05 f = 17. The covalently closed circular DNA HBV quantitative assessment method in liver puncture biopsies allows identifying HBsAgnegative chronic viral hepatitis B forms and also reflects the virus replication activity, which, in turn, makes it possible to assume further disease progression and evaluate the antiviral therapy effectiveness.
Competing Interests: The authors declare no conflict of interest.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies